ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EVMN vs LFCR // PIOTROSKI F-SCORE QUALITY

Evommune Inc. (NYSE) VS. Lifecore Biomedical Inc. (NASDAQ) • 15-METRIC TALLY: EVMN 1 — LFCR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EVMN VS. LFCR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EVMN LFCR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 85.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.87 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 2/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.5 65.4 -15.94 LFCR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $247.1M $246.8M $347.3K EVMN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EVMN REV LFCR REV EVMN GROSS % LFCR GROSS % EVMN FCF LFCR FCF
FY 2025 $13.0M $0 — — -$76.7M —
FY 2024 $7.0M $128.9M — 31.3% -$58.3M -$13.6M
FY 2023 — $0 — — — $257.0K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EVMN // BETA —
LFCR // BETA —